BSX · Earnings call · 2026Q3T · Full report

Mechanical Circulatory Support Positioning

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 8 · Surprise 24

Management said evidence from a competitor had raised questions about broad mechanical circulatory support use in high-risk PCI, but it continues to see a role for the therapy and emphasizes better patient selection. It is prioritizing AMI cardiogenic shock, where mortality approaches 50% and the condition occurs in up to 10% of patients with ST-elevation MI. Management cited DANGER-SHOCK as evidence that mechanical circulatory support can reduce mortality in these patients. It positions the Vitalist platform against the incumbent through a catheter design intended to improve positional stability during longer CCU treatment and strategies to reduce management complexity and vascular complications.

Key facts

• Boston Scientific shifted Vitalist development and clinical efforts from high-risk PCI to AMI cardiogenic shock and expects to initiate clinical efforts in 2027.
• Boston Scientific is moving the first Vitalist trial to AMI cardiogenic shock.
• Boston Scientific aims to bring Vitalist to market in 2030.
• Boston Scientific says the Vitalist platform has a novel catheter design intended to improve positional stability.
• Boston Scientific says its Vitalist platform has differentiated advantages over the current incumbent in treating shock.